TOP > 外国特許検索 > NOVEL GENETIC ABNORMALITY RELATED TO ACUTE LYMPHOBLASTIC LEUKEMIA, AND USES THEREOF

NOVEL GENETIC ABNORMALITY RELATED TO ACUTE LYMPHOBLASTIC LEUKEMIA, AND USES THEREOF

外国特許コード F170009136
整理番号 (S2016-0212-N0)
掲載日 2017年7月28日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP088570
国際公開番号 WO 2017111129
国際出願日 平成28年12月22日(2016.12.22)
国際公開日 平成29年6月29日(2017.6.29)
優先権データ
  • 特願2015-255179 (2015.12.25) JP
発明の名称 (英語) NOVEL GENETIC ABNORMALITY RELATED TO ACUTE LYMPHOBLASTIC LEUKEMIA, AND USES THEREOF
発明の概要(英語) The present invention addresses the problem of discovering a novel genetic abnormality, which is useful for the determination of treatment strategies or prognostic prediction of acute lymphoblastic leukemia, and contributing to the improvement of treatment outcomes. A genetic abnormality characterized by the formation of a fusion gene comprising the MEF2D gene and the BCL9 gene has been discovered from recurrent childhood acute lymphoblastic leukemia patients. This genetic abnormality will serve as a new indicator when determining treatment strategies.
従来技術、競合技術の概要(英語) BACKGROUND ART
Acute lymphoblastic leukemia (ALL; acute lymphoblastic leukemia) is the most frequent leukemia in childhood. 500 Cases per year in Japan and example occurs, and posterior to the long-term survival is 80%. As a feature of a wide variety ALL genetic abnormality (gene fusion, gene deletion, amplification, point mutations) develop with (non-patent document 1) are known. Then, by a difference in a genetic abnormality, life prognosis and various therapies of different reactivity. For example, TCF3-PBX1 fusion gene or fusion gene ETV6-RUNX1 ALL and is usually respond well to chemotherapy, a good prognosis. ALL BCR-ABL fusion gene but has a poor prognosis and, molecular target drugs BCR-ABL(imatinib, such as the second probe ) treatment with a clearly improved prognosis. TP53 Gene or IKZF1 gene point mutations, deletions or ALL, partial chromosome No. 21 with amplifications in ALL has a poor prognosis. NT5C2 Gene having a point mutation at a specific chemical therapy ALL (6 - mercaptopurine) (Patent Document 1) a resistance to. In recent large scale studies, activated mutations (point mutations or genetic fusion) one group of identified having ALL, by corresponding inhibitor was shown to be treated.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NAGOYA UNIVERSITY
  • 発明者(英語)
  • OKUNO Yusuke
  • KOJIMA Seiji
  • SUZUKI Kyogo
  • KAWASHIMA Nozomu
  • SEKIYA Yuko
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
名古屋大学の公開特許情報を掲載しています。ご関心のある案件がございましたら、下記まで電子メールでご連絡ください。

PAGE TOP

close
close
close
close
close
close